Post

CiMaas is featured in “How it’s done” by RTL-Z

On Saturday January 11, 2020, CiMaas appeared in a special program on new innovations in medicine. It is part of a production for the RTL-Z program ” How it’s done”. Broadcast time is 17.00. Saturday 28 march at 17.00; March 31 at 16:30 uur and April 2 at 10:30 the programme will be repeated

Post

Neuroplast and CiMaas join forces

Neuroplast and CiMaas, developers and producers of regenerative cell therapies, are setting up joint shop at the Brightlands Chemelot Campus in Geleen where they will be sharing a new laboratory and office space. Both companies currently employ around 30 people and expect to experience substantial growth.

Post

CiMaas featured in Brightlands media campaign

The national campaign – to the end of June 2019 – airs radiospots and runs advertisements in several national newspapers to draw attention to the collaboration between the University and Brightlands in developing solutions for important societal issues. CiMaas regenerates the immune system to fight cancer.

Post

CiMaas obtains gene therapy classification from EMA for its’ DC vaccine

Upon a recent application and discussion with EMA, Cimaas received the classification for its’ dendritic cell vaccine. EMA/CAT considers that the WT1-DC-Xcite-L1 falls within the definitions of a somatic cell therapy medicinal product and a gene therapy medicinal product and based on that is considered as gene therapy medicinal product as provided in Article 2(5)… Read more »

Post

CiMaas to collaborate with Kiadis on NK cell development after Cytosen acquisition

On June 6 2019, Kiadis Pharma (Amsterdam, The Netherlands) acquired Cytosen (USA). CiMaas had a long-standing collaboration with Cytosen to realize production of large numbers of Natural Killer Cells. The acquisition results in that CiMaas will continue the development of the Natural Killer Cell therapy now with Kiadis. 

Post

CiMaas to present at BIO Capital Europe 2019 in Amsterdam

CiMaas will present the company at BIO Capital Europe 2019 in Amsterdam. BIO Capital Europe is a meeting place for investors and life science companies. CiMaas will present its strategy and progress  on March 14 at 5 PM.

Post

CiMaas receives ATMP classification from EMA for NK cell product

CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This… Read more »

Post

CiMaas receives second tranche of financing

Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.